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Abstract: This study assessed the effects of a pilot best practice implementation enhancement program on the control of 
hypertension. We enrolled 697 consecutive known hypertensive patients with other vascular risk factors but free from 
overt vascular disease. There was no “control” group because it was considered unethical to deprive high-risk patients 
from “best medical treatment”. Following a baseline visit, previously trained physicians aimed to improve adherence to 
lifestyle measures and drug treatment for hypertension and other vascular risk factors. Both at baseline and at study com-
pletion (after 6 months), a 1-page form was completed showing if patients achieved treatment targets. If not, the reasons 
why were recorded. This program enhanced compliance with lifestyle measures and increased the use of evidence-based 
medication. There was a substantial increase in the number of patients who achieved treatment targets for blood pressure 
(p<0.0001) and other vascular risk factors. In non-diabetic patients (n=585), estimated vascular risk (PROCAM risk en-
gine) was significantly reduced by 41% (p<0.0001). There was also a 12% reduction in vascular risk according to the 
Framingham risk engine but this did not achieve significance (p=0.07). In conclusion, this is the first study to increase ad-
herence to multiple interventions in hypertensive patients on an outpatient basis, both in primary care and teaching hospi-
tals. Simple, relatively low cost measures (e.g. educating physicians and patients, distributing printed guidelines/brochures 
and completing a 1-page form) motivated both physicians and patients to achieve multiple treatment goals. Further work 
is needed to establish if the improvement observed is sustained. [ClinicalTrials.gov NCT00416611]. 
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INTRODUCTION 
  Cardiovascular disease (CVD) morbidity and mortality 
show a continuous relationship with both systolic and dia-
stolic blood pressure (BP) levels, without any evidence of a 
threshold down to at least 115/75 mmHg [1]. Hypertension is 
considered a major modifiable risk factor for stroke and also 
increases the risk for coronary heart disease (CHD), heart 
failure, chronic kidney disease (CKD) and peripheral arterial 
disease [2]. Randomized placebo-controlled trials showed 
that BP lowering is associated with a reduction in the risk of  
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fatal and non-fatal stroke (by about 30-40%), while CHD 
events are reduced to a lesser extent (by about 20%) [3-8]. 
Comparative studies showed that for a similar BP lowering, 
differences in vascular risk reduction between various drug 
classes are small [7, 9]. 
  According to the National Health and Nutrition Examina-
tion Survey (NHANES) data, the prevalence of hypertension 
increased significantly between 1988 and 2004 [10]. Be-
tween 1988 to 1994 and 1999 to 2004, BP control increased 
in men from 39% to 51% (p<0.05) but did not change sig-
nificantly in women (35% to 37%) [10]. Control rates were 
lower in persons older than 70 years and in patients with 
type 2 diabetes mellitus (T2DM) or CKD [10]. Similar hy-
pertension control rates were recently reported in Europe 
[11]. 
  In the present study we assessed whether a best practice 
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trol of hypertension and other vascular risk factors in hyper-
tensive patients without clinically overt vascular disease. 
STUDY DESIGN AND METHODS 
  The IMPULSION (Implementation of guidelines for the 
management of arterial hypertension). Study was conducted 
during 2006-2007 under the auspices of the Regional   
(Bureau) Authority of the Ministry of Health for Northern 
Greece-Central Macedonia. The Working Groups for the 
identification and treatment of hypertension of the Hellenic 
Atherosclerosis Society and the Greek Society of General 
Practitioners jointly conducted the study. The study received 
ethical approval and informed consent was obtained from all 
patients before enrolment. This study is registered as Clini-
calTrials.gov NCT00416611. 
Definition of Hypertension, Dyslipidemia, T2DM and 
Metabolic Syndrome (MetS)  
  At baseline, BP was measured in both arms by a trained 
physician using a standard mercury sphygmomanometer 
after 5 min rest with the subject in the sitting position. The 
arm with the highest reading was selected [2, 12]. The mean 
of 2 measurements, taken 1 min apart, was recorded in the 
selected arm. The disappearance of Korotkoff sound (onset 
of phase
 5) was used to define diastolic BP (DBP). All pa-
tients were on treatment with antihypertensive medication 
[13]. Hypertension was considered to be controlled if the BP 
was 140/90 mmHg. In patients with T2DM, BP was con-
sidered to be controlled when it was 130/80 mmHg [13]. 
  Patients were considered to have dyslipidemia when: i) 
low density lipoprotein cholesterol (LDL-C) levels were 
<160 mg/dl (4.2 mmol/l), <130 mg/dl (3.4 mmol/l), <100 mg/dl 
(2.6 mmol/l) or <70 mg/dl (1.8 mmol/l) in lower risk,   
moderate/moderately high risk, high risk (CHD or CHD risk 
equivalents) or very high risk (CHD with T2DM or MetS or 
smoking) patients, respectively [14], ii) high density lipopro-
tein cholesterol (HDL-C) levels were < 40 mg/dl (1.0 mmol/l) 
in both genders [15], iii) non-HDL-C levels were >30 mg/dl 
higher than the LDL-C target levels (according to risk status) 
in patients with triglyceride (TG) levels >200 mg/dl   
(2.2 mmol/l) [14], or, iv) patients were on lipid-lowering 
treatment. Only patients with TG levels <400 mg/dl   
(4.5 mmol/l) were included in the study, since the Friede-
wald formula [LDL-C = total cholesterol - (TG / 5 + HDL-C) 
in mg/dl] was used to calculate LDL-C levels. 
  According to the American Diabetes Association criteria, 
patients were considered to have T2DM when the fasting 
venous plasma glucose levels were 126 mg/dl (7.0 mmol/l) 
on 2 consecutive assessments or if they were on treatment 
for T2DM [16]. 
  Participants with 3 or
 more of the following criteria [ac-
cording to the National Cholesterol Educational Program 
Adult Treatment Panel III (NCEP ATP III) report] [17] were 
considered to have MetS: 
1.  Waist circumference (WC) >102 cm in men and
 >88 cm 
in women 
2. Fasting  TG  150 mg/dl (1.7
 mmol/l) or on treatment for 
TG 
3. HDL-C  <40
 mg/dl (1.0 mmol/l) in men and <50 mg/dl 
(1.3 mmol/l) in
 women or on treatment for HDL-C 
4. BP  130/85 mmHg or use of antihypertensive medication 
5.  Fasting venous plasma glucose
 110 mg/dl (6.1 mmol/l) 
or treatment 
Study Design - Study Cohort  
  This was a best practice prospective study. Physicians 
from Health Centres (primary care) or Hospitals (secondary 
care) recruited consecutive consenting patients with known 
hypertension, with or without other vascular risk factors, but 
free of overt CVD at baseline. A total of 697 hypertensive 
patients were enrolled. Seven additional patients that were 
planning to move to a region outside the program area did 
not agree to participate. These 7 patients were not different 
in their demographic or clinical characteristics from those 
who agreed to participate. Besides, their number is so small 
that it could not have changed the baseline status or final 
outcome. Apart from these 7 patients, no other patient re-
fused to participate. 
  During the first visit, personal and family history, as well 
as medication, was recorded in a specially designed 1-page 
form (Table 1). A physical examination was also carried out. 
Afterwards, laboratory tests were performed at the hospital 
following a 12h fast, at which time a second physical exami-
nation was performed to confirm the clinical findings. 
Intervention 
  Before study initiation and during the study physicians 
attended an educational and problem solving program. In all 
there were 7 meetings. The educational components were 
presentation of current guidelines for hypertension, dyslipi-
demia, T2DM, MetS and nutrition (specific diets based on a 
Greek variation of the Mediterranean diet). Up to date treat-
ment protocols were also discussed. This took 4 meetings. 
The other 3 meetings were for technical problem solving 
during the study. To facilitate physician education we sup-
plied current guidelines for the treatment of hypertension and 
other risk factors and an information brochure for the pa-
tients providing advice on lifestyle measures. All these 
documents (Patient Data Form, Guidelines for the Physician, 
Patient Brochure) were written using a computer and photo-
copies were distributed. This was deemed to be a low cost 
procedure. The physicians agreed to participate as part of 
their continuing medical education program. They also 
wanted to have more patients at goal for CVD risk factors. 
  During the study, an intensification of treatment in terms 
of lifestyle advice, new drugs or titration of already pre-
scribed drugs was implemented aiming to reach multiple 
treatment targets. Physicians also advised each patient to 
improve compliance with a healthier lifestyle and drug 
treatment. The lifestyle changes included smoking cessation, 
weight reduction, increased physical activity, decreased salt 
intake, moderate alcohol consumption and a Mediterranean 
diet. The patients were advised as to how often they should 
consume non-refined cereals (e.g. whole grain bread, pasta 
and rice), potatoes, fruits, vegetables, legumes, fish, red meat 
and products, poultry, full fat dairy products (cheese, yo-
ghurt and milk), olive oil in cooking and alcoholic beverages 
[18]. Compliance to the Mediterranean diet was assessed 
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Follow-up 
  In Greece monthly visits are required by health care pro-
viders for the renewal (refill) of prescriptions by general 
practitioners or outpatient clinic physicians. Consequently, 
patients had to visit their physician every month. At the 6
th  
 
treatment month (the final visit) physicians completed the 
same form for each patient that included 2 more questions. 
Does the patient still have hypertension? And if yes, what 
did the physician do about it? Physicians were aware of this 
question from visit 1 and we believe that this was a motiva-
tional factor. 
Table 1.   Patient Data Form 
PATIENT DATA 
Initials:                                                                  Patient Number: 
Male:   Female:   Date  of  birth: 
 
Height:                           cm         Weight:                   kg        Waist circumference:               cm 
Smoker:   Yes    No    Ex (quit 6 months ago) 
Cultural level (years of school):  0-6          6-9            9-12     >12 
Awareness of hypertension:  Yes            No   Family history of CHD:  Yes               No 
 
Chol:      TG:             HDL-C:              LDL-C: 
Glucose:      Urea:             Creatinine:              Uric acid: 
AST:      ALT:             CK:               HbA1c: 
SBP:      DBP:             Pulse: 
 
Antihypertensive Drug Treatment:      Other Drugs: 
Diuretic:   Yes   No   Combination:  Yes   No 
ACEI:     Yes   No   Antidiabetics:  Yes   No 
ARB:     Yes   No   Statin:   Yes   No 
-blocker:    Yes   No   Fibrate:   Yes   No 
Ca-blocker:    Yes   No   ASA:   Yes   No 
Other:     Yes   No   Clopidogrel:  Yes   No   
 
Is the patient on target for BP?   Yes     No         If not what did you do?   
 
Dose increase:    Yes    No    Drug side-effects:      
Change of drug:    Yes    No 
Additional  drug:   Yes   No 
New  combination:   Yes   No       Next  visit:   Implementation of Guidelines in Hypertension  The Open Cardiovascular Medicine Journal, 2009, Volume 3    29 
  There was no “control” group because all patients had 
hypertension, as well as other vascular risk factors. It was 
therefore deemed unethical to deprive them of “best medical 
treatment”. Any changes at the final visit were compared 
with baseline values. The estimated vascular risk was 11.2 
and 12.2% at baseline in non-diabetic patients [assessed with 
the PROspective CV Münster (PROCAM) and Framingham 
risk engine, respectively; Table 2] but this was calculated 
using “on treatment” values. In this context, all patients were 
taking at least 1 antihypertensive drug and 24.8% of the 
whole study population were on statins. Furthermore, 16% 
had T2DM (a CHD risk equivalent [14, 17]) and about 43% 
had MetS. 
Laboratory-Based Assessment 
  After an overnight 12h fast, serum total cholesterol, 
HDL-C, TG, transaminases, creatinine and uric acid levels 
and plasma glucose levels were measured using an Olympus 
AU 560 autoanalyser (Medicon Hellas, Athens, Greece) and 
respective reagents (Olympus Diagnostica GmbH, Clare, 
Ireland). LDL-C was calculated using the Friedewald for-
Table 2.  Patient Characteristics at Baseline and at the End of the Study (i.e. After 6 Months) 
  Baseline n=697  End of Study n=697  P 
Age (years ± SD)  59±8     
Men (%)  38.7     
Years of education (%) 
<6 
6-9 
10-12 
University education 
54.6 
24.8 
13.7 
6.9    
Body weight (kg)  82±12  79±13  NS 
Waist circumference (cm)  97±13  96±9  NS 
Smoking (%)  33.6  32.2  NS 
Systolic BP (mmHg)  154±19  136±13  <0.0001 
Diastolic BP (mmHg)  92±11  83±7  <0.0001 
At systolic BP target (%)  21.8  54.7  <0.0001 
At diastolic BP target (%)  32.7  64.2  <0.0001 
At both systolic and diastolic BP target (%)  19.3  49.2  <0.0001 
Dyslipidemia (%)  59.7  53.6  NS 
Total cholesterol (mg/dl)  223±36  205±28  <0.0004 
Triglycerides (mg/dl)  153±44  134±32  <0.002 
LDL-C (mg/dl)  143±31  125±23  <0.0001 
HDL-C (mg/dl)  44±13  45±14  NS 
On lipid targets (in the whole population, n=697) (%)  44.6  72.8  <0.0001 
On lipid targets (in patients on statins) (%)  17.2 (n=173)  68.8 (n=273)  <0.0001 
Type 2 diabetes mellitus (%)  16  14.8  NS 
Fasting plasma glucose (mg/dl)  106±32  101±22  <0.005 
HbA1c (%)(in diabetic patients, n=112)  7.4±0.5  6.1±0.6  <0.0001 
MetS (men)  37.8  29.3  <0.0001 
MetS (women)   45.9  34.2  <0.0001 
Serum creatinine (mg/dl)  0.90±0.34  0.89±0.27  NS 
Serum uric acid (mg/dl)  5.5±2.4  5.3±2.6  NS 
AST (IU/l)  24±9  23±8  NS 
ALT (IU/l)  25±11  24±9  NS 
10-year patient risk PROCAM % (in non-diabetic patients, n=585)  11.2  6.6 (-41%)  <0.0001 
10-year patient risk Framingham % (in non-diabetic patients, n=585)  12.2  10.7 (-12%)  NS 
BP, blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; HbA1c, glycated hemoglobin; AST, aspartate transaminase; ALT, 
alanine transaminase; PROCAM, prospective CV münster study; MetS, metabolic syndrome; NS, not significant. 30    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Karagiannis et al. 
mula. Glycated hemoglobin (HbA1c) was determined in dia-
betic patients with high performance liquid chromatography 
(HPLC) using the Menarini Diagnostics (Menarini, Greece) 
reagents (reference range: 4.2-6.5%). All hospital laborato-
ries participate in internal and external quality control 
schemes. 
PROCAM and Framingham 10-Year Risk Estimates  
  The PROCAM Trial risk engine [http://www.chd-
taskforce.com] calculates the 10-year risk for fatal or non-
fatal myocardial infarction (MI), taking into consideration 
age, LDL-C, HDL-C, TG, smoking habit (including ex-
smokers), fasting blood glucose, systolic BP (SBP), current 
antihypertensive treatment and family history of premature 
CVD. 
 The Framingham risk engine [http://www.chd-
taskforce.com] does not consider impaired fasting glucose, 
ex-smoking, high TG levels and family history of premature 
CVD when calculating the 10-year risk. Moreover, when the 
10-year risk is >30% the program does not provide an exact 
number. 
  Since we are comparing pre- with post-intervention cal-
culated risk we allowed an additional ± 5 years of age be-
yond the limits set by the PROCAM risk engine. This proce-
dure allowed us to compare a greater number of patients. 
Statistical Analysis 
  Analyses were carried out using the SPSS 12.0 software 
(SPSS Inc., Chicago, IL). All variables had a normal distri-
bution (assessed with the Kolmogorov-Smirnov test) and are 
reported as mean and standard deviation (SD). The paired 
samples t-test and Chi-square test were used to evaluate 
changes in continuous and categorical variables, respec-
tively. A two tailed p <0.05 was considered significant. 
RESULTS 
Baseline Data 
  The baseline characteristics of the 697 hypertensive   
patients recruited in the study are shown in Tables 2 and 3. 
Twenty seven additional patients attended the baseline visit 
but did not attend the final visit (after 6 months) and are not 
included in the final analysis. These 27 patients represent 
3.9% of the recruited population. 
  As already mentioned, all patients were known hyperten-
sives and were receiving at least 1 antihypertensive drug; the 
mean number of antihypertensive drugs per patient was 1.4. 
At baseline, 21.8% of patients were on target for SBP (140 
mmHg), 32.7% for DBP (90 mmHg) and 19.3% for both 
SBP and DBP (add to Table 2). Although the prevalence of 
dyslipidemia was 59.7%, only 24.8% of patients were re-
ceiving statins. At baseline, 44.6% of the whole population 
was at their lipid targets. Among patients on statins, 17.2% 
were at their target. At baseline, 12.6% of patients were   
taking aspirin (ASA). 
Treatment and Control of Hypertension and Other   
Vascular Risk Factors 
  As shown in Tables 2 and 3, the vascular risk factor pro-
file improved significantly during the 6-month follow-up 
associated with a greater compliance to lifestyle advice 
(there was a 2-unit increase in adherence to the recom-
mended diet) and a more aggressive pharmacological inter-
vention. 
  At the end of the study 54.7% of the patients were on 
target for SBP, 64.2% for DBP and 49.2% for both SBP and 
DBP (p<0.0001 for all comparisons vs. baseline). Compared 
with BP at baseline, average SBP was reduced by 18 mmHg 
(p<0.0001) and DBP by 9 mmHg (p<0.0001). The mean 
number of antihypertensive drugs per patient increased from 
1.4 to 2.8 (p<0.0001) and the use of fixed combinations of 
antihypertensive drugs increased from 20.3% to 37.2% 
(p<0.0001). 
  The prevalence of dyslipidemia at the end of the study 
decreased by 10.2% (53.6% vs. 59.7% at baseline, p=0.12). 
There was a significant 58.1% increase in the percentage of 
patients on statins (from 24.8% to 39.2%, p<0.0001). At the 
end of the study, 72.8% of the whole population was at their 
lipid targets (p<0.0001 compared with baseline). Moreover, 
68.8% of patients on statins achieved their targets (p<0.0001 
compared with baseline). 
  There was a significant improvement in the glycemic 
control in diabetic patients; HbA1c decreased by 18% (6.1% 
vs. 7.4% at baseline, p<0.0001). The prevalence of T2DM at 
the end of study decreased by 7.5% (14.8% vs. 16% at base-
line, p=0.09). At the end of the study, 14.2% of patients were 
on antidiabetic drugs and 0.6% were only on diet. 
  There was an increase in the use of ASA by 47% (18.5% 
vs. 12.6% at baseline, p<0.0001). 
  There was a reduction in the incidence of MetS by 23% 
in men (29.3% vs. 37.8% at baseline, p<0.0001) and by 26% 
in women (34.2% vs. 45.9% at baseline, p<0.0001). 
Framingham and PROCAM 10-Year CVD Risk Esti-
mates 
  In patients without T2DM (n=585, 84% of the study 
population), the estimated 10-year CHD risk according to the 
PROCAM risk engine was significantly reduced by 41% 
(6.6% vs. 11.2% at baseline, p<0.0001). The estimated 10-
year risk according to the Framingham risk engine in the 
same population was reduced by 12% (10.7% vs. 12.2% at 
baseline, p=0.07). We did not estimate the vascular risk in 
patients with T2DM (n=112, 16% of the study population) 
because T2DM is considered a CHD risk equivalent (esti-
mated 10-year risk > 20%). 
Safety and Tolerability 
  Medication was well tolerated and the only reported ad-
verse effects that occurred in more than 2% of the partici-
pants were dry cough in users of angiotensin converting en-
zyme inhibitors (mainly) and of angiotensin receptor block-
ers (less frequently), as well as ankle oedema in users of cal-
cium antagonists. 
DISCUSSION 
  Our pilot program was effective at implementing multi-
factorial evidence-based treatment in hypertensive patients, 
with or without other vascular risk factors, and free of CVD 
at baseline. Lifestyle measures and aggressive pharmacol-
ogical treatment was associated with a significant increase in 
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21.8% to 54.7%), for DBP (from 32.7% to 64.2%) and for 
both SBP and DBP (from 19.3% to 49.2%) (p<0.0001 for all 
comparisons). There was also a 41% reduction in estimated 
10-year CHD risk according to the PROCAM risk engine in 
non-diabetic patients (from 11.2% to 6.6%; p<0.0001). In the 
same population, estimated CHD risk according to the 
Framingham risk engine also decreased by 12% but this fall 
did not achieve significance (p=0.07). Thus, it is possible 
that engines incorporating several additional variables (e.g. 
PROCAM) capture the vascular risk reduction achieved by a 
multifactorial approach in a more obvious manner than other 
calculators that consider fewer factors (e.g. Framingham). 
Whether this means that new broad based risk calculators are 
required to accurately assess multifactorial approaches to 
vascular risk reduction remains to be established. 
  The present study is part of 4 pilot best practice imple-
mentation enhancement programs aimed at improving risk 
factor control in 4 different populations of patients with: (i) 
hypertension (the present study), (ii) dyslipidemia [Hatzi-
tolios et al, unpublished observations], (iii) MetS [19], or, 
(iv) T2DM [Athyros et al, unpublished observations]. These 
programs were similarly effective. 
  Large surveys in the US, Canada and Europe (Germany, 
Sweden, England, Spain and Italy) showed that only 29%, 
17% and 10% of hypertensive patients, respectively, had BP 
levels less than 140/90 mmHg [20]. These findings might be 
explained by the more aggressive guidelines for hyperten-
sion treatment in the US compared with Europe. A recent 
cross-sectional analysis of the 2004 data from CardioMoni-
tor, an ongoing survey in ambulatory patients with CVD in 
the US and in 5 European countries (Germany, France, Eng-
land, Spain and Italy) showed an improvement in control 
rates [11]. The rate of hypertension control (<140/90 mmHg) 
was 63% in US and 31-46% in Europe [11]. Several studies 
evaluated hypertension control rates in Greece [21-25]. In 
2001, the Greek component of the European Prospective 
Investigation into Cancer and nutrition (EPIC) study (26, 
913 volunteers from several regions of Greece) showed that 
BP was controlled only in 15.2% of hypertensive patients 
[21]. In the Attica study (carried out between 2001 and 
2002), only 34% of treated hypertensive patients were ade-
quately controlled [22]. Two smaller regional studies showed 
that among treated hypertensive patients, 49.5 and 49.1% (of 
344 and 103 treated patients, respectively) were controlled 
[23, 24]. In the Hypertension Study in General Practice in 
Hellas (HYPERTENSHELL; 11, 950 participants), which 
was conducted during 2002-2004 across Greece, 32.8% of 
treated hypertensive patients were adequately controlled 
[25]. Most of these levels of control are below those 
achieved in the current study (i.e. 49.2%). 
  The 2003 and 2007 European Society of Hypertension / 
European Society of Cardiology guidelines state that the 
management of hypertension should depend on the estimated 
global vascular risk [13, 26]. This is based on the fact that 
only 20% of hypertensive patients have hypertension alone 
while the majority has 1 or more additional risk factors [27, 
28]. This coexistence of risk factors, which was also evident 
in our study, produces a total vascular risk that is greater 
than the sum of the individual factors [29, 30]. It is estimated 
that in patients with BP of 140-159/90-99 mmHg and at least 
1 additional risk factor, reducing SBP by 12 mmHg for 10 
years will prevent 1 death for every 11 treated hypertensive 
patients [31]. 
  In our study, 59.7% of hypertensive patients had dyslipi-
demia at baseline. The increase in the use of statins (from 
24.8% to 39.2%, p<0.0001) contributed to the significantly 
improved lipid profile (total cholesterol, LDL-C and TG but 
not HDL-C levels). The co-existence of hypertension and 
dyslipidemia confers a greater increase in vascular risk than 
would be expected with either risk factor alone [32]. Two 
trials evaluated the benefits associated with the use of statins 
specifically in hypertensive patients. In the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
- Lipid-Lowering Trial (ALLHAT-LLT) (10, 355 hyperten-
sive patients), pravastatin (40 mg/d) did not reduce CHD 
events, stroke and all cause mortality significantly more than 
“usual care” [33]. In contrast, in the Anglo-Scandinavian 
Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-
LLA; 10, 305 hypertensive patients with at least 3 other vas-
cular risk factors but free of CHD), atorvastatin (10 mg/d) 
Table 3.  Drug Treatment at Baseline and at the End of the Study (i.e. After 6 Months) 
  Baseline n=697  End of Study n=697  p 
Diuretics 34.5  48.7  <0.0001 
ACEIs 30.3  49.6  <0.0001 
ARBs 29.6  45.2  <0.0001 
Beta-blockers 24.3  31.7  NS 
Calcium antagonists  29.8  43.5  <0.0001 
Fixed combinations  20.3  37.2  <0.0001 
Antidiabetic drugs  13.6  14.2  NS 
Statins 24.8  39.2  <0.0001 
Fibrates 1.3  1.8  NS 
Aspirin 12.6  18.5  <0.0001 
All numbers express percent of patients.  
ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; NS, not significant. 32    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Karagiannis et al. 
significantly reduced vascular events (36%; p=0.0005) and 
stroke (27%; p=0.024) compared with placebo [34]. This 
discrepancy may be related to several factors, among which 
is the extent of LDL-C lowering, which was greater in the 
ASCOT-LLA trial (17 vs. 29% relative reduction) [33, 34]. 
A recent meta-analysis showed that statin therapy reduces 
vascular morbidity and mortality to the same extent in hyper-
tensive and normotensive patients [35]. There is evidence in 
secondary prevention that the combination of a statin with 
angiotensin converting enzyme inhibitors reduces the risk of 
vascular events more than either drug alone [36]. Further-
more, statins may beneficially influence the BP and some 
antihypertensive drugs can have a beneficial, neutral or ad-
verse effect on the lipid profile [37-39]. However, we cannot 
comment on these potential effects using our results. 
  Current guidelines state that low-dose ASA should be 
prescribed to hypertensive patients with established CVD, as 
well as to patients free of CVD but older than 50 years, with 
a moderate increase in serum creatinine levels or with a high 
vascular risk [13]. Antiplatelet therapy should be started af-
ter achievement of BP control [13]. The Hypertension Opti-
mal Treatment (HOT) trial showed that treatment of hyper-
tensive patients with ASA resulted in a 15% reduction in 
major vascular events and a 36% reduction in acute MI [40]. 
There was no effect on stroke and no increase in intracere-
bral haemorrhage but a 65% increased risk of major hemor-
rhagic events was observed [40]. The relatively low percent-
age of patients receiving ASA in our study (18.5%) may 
reflect physician reluctance to accept an increased risk of 
bleeding in a primary prevention setting. 
  In the UK Prospective Diabetes Study (UKPDS), hyper-
tensive patients with T2DM benefited from intensive blood 
glucose control mainly in terms of microvascular complica-
tions (a 37% reduction in microvascular complications for 
each 1% reduction in HbA1c) [41]. Other studies showed that 
improved glycemic control (by lifestyle measures and phar-
maceutical interventions) also protects against macrovascular 
complications [42, 43]. In our study, 16% of hypertensive 
patients had T2DM and pharmacologic treatment in combi-
nation with lifestyle measures resulted in a significant reduc-
tion in HbA1c (from 7.4% to 6.1%, p<0.0001). The preva-
lence of T2DM at the end of study decreased by 7.5% (from 
16% to 14.8%, p=0.09). 
  In our study, 37.8% of men and 45.9% of women had 
MetS at baseline. The prevalence of MetS in the Western 
World, including Mediterranean Countries, is high [44] but 
awareness, treatment and control of MetS and its compo-
nents remain poor [45-47]. MetS confers an increased risk 
for vascular morbidity and mortality [48-53] and all-cause 
mortality [48], even in Mediterranean Countries and in the
 
absence of T2DM and/or clinically evident CVD [49, 50, 54, 
55]. The combination of lifestyle interventions and drug 
treatment for all vascular risk factors in our patients resulted 
in a significant reduction in the prevalence of MetS (from 
37.8% to 29.3% in men and from 45.9% to 34.2% in women; 
p<0.0001 for both comparisons). 
LIMITATIONS 
  In this study there was no control group due to ethical 
restrictions, as explained above. Each patient acted as his/her 
own control and had been on a regular treatment regime for 
an average of 23 months (range: 8-72 months) prior to inclu-
sion in the study. The estimated fall in vascular risk in hyper-
tensive patients was calculated after intervention for 6 
months. The observed benefits may decrease if adherence to 
lifestyle measures and pharmacological treatment deterio-
rates in the long run. The PROCAM and Framingham calcu-
lations were based on a treated population both at baseline 
and at the end of the study. Twenty seven patients did not 
attend the final visit (after 6 months). These patients repre-
sent only 3.9% of the baseline population and therefore they 
were not included in the final analysis. Nevertheless, this 
should be considered among the limitations of the study. 
CONCLUSIONS 
  This is the first study to increase adherence to multiple 
interventions in hypertensive patients on an outpatient basis, 
both in primary care and teaching hospitals. Simple, rela-
tively low cost measures (e.g. educating physicians and pa-
tients, distributing printed guidelines/brochures and complet-
ing a 1-page form) were associated with achieving treatment 
goals for multiple vascular risk factors. Further work is 
needed to establish the cost effectiveness and long-term 
benefits of such programs. 
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